| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Dipartimento di Medicina Interna, Università Tor Vergata, Rome, Italy;
Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanita’, Rome, Italy; and
Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London, United Kingdom
High expression of IL-21 and/or IL-21R has been described in T cell-mediated inflammatory diseases characterized by defects of counterregulatory mechanisms. CD4+CD25+ regulatory T cells (Treg) are a T cell subset involved in the control of the immune responses. A diminished ability of these cells to inhibit T cell activation has been documented in immune-inflammatory diseases, raising the possibility that inflammatory stimuli can block the regulatory properties of Treg. We therefore examined whether IL-21 controls CD4+CD25+ T cell function. We demonstrate in this study that IL-21 markedly enhances the proliferation of human CD4+CD25– T cells and counteracts the suppressive activities of CD4+CD25+ T cells on CD4+CD25– T cells without affecting the percentage of Foxp3+ cells or survival of Treg. Additionally, CD4+CD25+ T cells induced in the presence of IL-21 maintain the ability to suppress alloresponses. Notably, IL-21 enhances the growth of CD8+CD25– T cells but does not revert the CD4+CD25+ T cell-mediated suppression of this cell type, indicating that IL-21 makes CD4+ T cells resistant to suppression rather than inhibiting CD4+CD25+ T cell activity. Finally, we show that IL-2, IL-7, and IL-15, but not IL-21, reverse the anergic phenotype of CD4+CD25+ T cells. Data indicate that IL-21 renders human CD4+CD25– T cells resistant to Treg-mediated suppression and suggest a novel mechanism by which IL-21 could augment T cell-activated responses in human immune-inflammatory diseases.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work received support from the Fondazione Umberto di Mario, Rome; the Broad Medical Research Program Foundation (Grant IBD-0154R); Ministero dell’ Istruzione, dell’ Università e della Ricerca, Grant 2004065777-004, Italy; and Giuliani SpA, Milan, Italy.
2 Address correspondence and reprint requests to Dr. Giovanni Monteleone, Dipartimento di Medicina Interna, Università Tor Vergata, Via Montpellier, 1, Rome, Italy. E-mail address: Gi.Monteleone{at}Med.uniroma2.it
3 Abbreviations used in this paper: Treg, regulatory T cell; Ann V, annexin V.
This article has been cited by other articles:
|
|
 |
|
  M. B. Ahmed, N. Belhadj Hmida, N. Moes, S. Buyse, M. Abdeladhim, H. Louzir, and N. Cerf-Bensussan IL-15 Renders Conventional Lymphocytes Resistant to Suppressive Functions of Regulatory T Cells through Activation of the Phosphatidylinositol 3-Kinase Pathway J. Immunol., June 1, 2009; 182(11): 6763 - 6770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. D. Davis, B. Brady, R. F. Kefford, M. Millward, J. Cebon, B. K. Skrumsager, U. Mouritzen, L. T. Hansen, K. Skak, D. Lundsgaard, et al. Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial Clin. Cancer Res., March 15, 2009; 15(6): 2123 - 2129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. D'Alise, V. Auyeung, M. Feuerer, J. Nishio, J. Fontenot, C. Benoist, and D. Mathis The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors PNAS, December 16, 2008; 105(50): 19857 - 19862. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Watanabe, V. P. Rao, T. Poutahidis, B. H. Rickman, M. Ohtani, S. Xu, A. B. Rogers, Z. Ge, B. H. Horwitz, T. Fujioka, et al. Cytotoxic-T-Lymphocyte-Associated Antigen 4 Blockade Abrogates Protection by Regulatory T Cells in a Mouse Model of Microbially Induced Innate Immune-Driven Colitis Infect. Immun., December 1, 2008; 76(12): 5834 - 5842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schneider, M. Rieck, S. Sanda, C. Pihoker, C. Greenbaum, and J. H. Buckner The Effector T Cells of Diabetic Subjects Are Resistant to Regulation via CD4+FOXP3+ Regulatory T Cells J. Immunol., November 15, 2008; 181(10): 7350 - 7355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Meresse, J. Verdier, and N. Cerf-Bensussan The cytokine interleukin 21: a new player in coeliac disease? Gut, July 1, 2008; 57(7): 879 - 881. [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Thompson, B. D. Curti, B. G. Redman, S. Bhatia, J. S. Weber, S. S. Agarwala, E. L. Sievers, S. D. Hughes, T. A. DeVries, and D. F. Hausman Phase I Study of Recombinant Interleukin-21 in Patients With Metastatic Melanoma and Renal Cell Carcinoma J. Clin. Oncol., April 20, 2008; 26(12): 2034 - 2039. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Smyth, M. W.L. Teng, J. Sharkey, J. A. Westwood, N. M. Haynes, H. Yagita, K. Takeda, P. V. Sivakumar, and M. H. Kershaw Interleukin 21 Enhances Antibody-Mediated Tumor Rejection Cancer Res., April 15, 2008; 68(8): 3019 - 3025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Clough, C. J. Wang, E. M. Schmidt, G. Booth, T. Z. Hou, G. A. Ryan, and L. S. K. Walker Release from Regulatory T Cell-Mediated Suppression during the Onset of Tissue-Specific Autoimmunity Is Associated with Elevated IL-21 J. Immunol., April 15, 2008; 180(8): 5393 - 5401. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Caprioli, M. Sarra, R. Caruso, C. Stolfi, D. Fina, G. Sica, T. T. MacDonald, F. Pallone, and G. Monteleone Autocrine Regulation of IL-21 Production in Human T Lymphocytes J. Immunol., February 1, 2008; 180(3): 1800 - 1807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Li and C. Yee IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes Blood, January 1, 2008; 111(1): 229 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. D. Nelson, A. G. Zenovich, H. C. Ott, C. Stolen, G. J. Caron, A. Panoskaltsis-Mortari, S. A. Barnes III, X. Xin, and D. A. Taylor Sex-Dependent Attenuation of Plaque Growth After Treatment With Bone Marrow Mononuclear Cells Circ. Res., December 7, 2007; 101(12): 1319 - 1327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. D. Davis, K. Skak, M. J. Smyth, P. E.G. Kristjansen, D. M. Miller, and P. V. Sivakumar Interleukin-21 Signaling: Functions in Cancer and Autoimmunity Clin. Cancer Res., December 1, 2007; 13(23): 6926 - 6932. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
